TYO:4543
Founded in 1921 by a group of physicians including the legendary bacteriologist Dr. Kitasato Shibasaburo, Terumo Corporation has evolved from a Japanese thermometer manufacturer into one of the world’s leading medical technology companies. With FY2024 revenue surpassing 1 trillion yen for the first time, operations in 160+ countries, and a market capitalization of approximately 3.1 trillion yen, Terumo is the quiet global giant behind the catheters, blood management systems, and organ preservation technologies that save millions of lives each year. This report examines its product empire, financial engine, M&A strategy, and what it all means for international partners.
Company Overview
| Item | Details |
|---|---|
| Official Name | Terumo Corporation (テルモ株式会社) |
| Founded | September 17, 1921 (as Sekisen Taionki Kabushikigaisha / Red Line Thermometer Corp.) |
| Headquarters | Shibuya, Tokyo, Japan |
| Stock Listing | Tokyo Stock Exchange Prime (TYO: 4543) |
| President & CEO | Shinjiro Sato |
| Employees | 30,000+ worldwide |
| Global Reach | 160+ countries and regions |
| FY2024 Revenue | ¥1,036.2 billion (~$6.84B USD) |
| Market Cap | ~¥3.11 trillion (~$20.5B USD, as of April 2026) |
| Mission | “Contributing to Society through Healthcare” |
Terumo’s founding story is deeply rooted in Japanese medical history. During World War I, Japan’s supply of clinical thermometers from Germany, the UK, and the US was cut off. Dr. Kitasato Shibasaburo — the same scientist who co-discovered the plague bacillus — assembled a team of physicians to manufacture Japan’s first domestically-produced thermometers. The company’s first product, the “Jintan Taionkei,” became the foundation for a century of medical innovation. In 1963, Terumo launched Japan’s first disposable syringe, and by 1971, it had established its first overseas offices in the United States and Europe.
Business Segments
Terumo operates through three major business segments, each addressing distinct and critical areas of global healthcare. The company’s portfolio spans over 50,000 products and services delivered through 3 core companies and 9 businesses.
Cardiac & Vascular Company (C&V) — ~60% of Revenue
The Cardiac & Vascular segment is Terumo’s largest and most strategically important division, contributing over 60% of total revenue. This segment encompasses:
- Terumo Interventional Systems (TIS) — A global leader in transradial intervention (TRI), pioneering radial artery access for catheterization procedures for over 30 years. Products include guide wires, catheters, sheaths, and closure devices
- Terumo Cardiovascular (TCV) — Cardiopulmonary bypass systems, oxygenators, heart-lung machines, and endoscopic vessel harvesting products for cardiac surgery
- Terumo Aortic — Stent grafts and surgical grafts for aortic repair, formed by combining Vascutek and Bolton Medical
- Terumo Neuro — Formerly MicroVention; coils, flow diverters, and stent retrievers for neurovascular treatment of aneurysms and stroke
Blood and Cell Technologies (TBCT) — ~25% of Revenue
Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis, and cell therapy technologies. Key products include:
- Rika Plasma Collection System — Next-generation automated plasma collection driving strong U.S. market growth
- Whole Blood Collection Systems — Comprehensive solutions for blood banks and transfusion services
- Cell Therapy Technologies — Cell processing and expansion platforms for the emerging regenerative medicine market
- OrganOx metra — Normothermic machine perfusion system that keeps donor livers “alive” outside the body, dramatically improving transplant outcomes
Medical Care Solutions (TMCS) — ~15% of Revenue
The Medical Care Solutions segment covers essential clinical products used in everyday hospital and outpatient care:
- Hospital Care — IV sets, syringes, infusion pumps, and blood glucose monitoring systems
- Pharmaceuticals (PLAJEX) — Pre-filled syringe systems for pharmaceutical partners, showing strong overseas growth
- Diabetes Care — Blood glucose meters and insulin delivery devices
- Peritoneal Dialysis — Home-based dialysis solutions
Financial Analysis
FY2024 Full-Year Results (April 2024 – March 2025)
| Metric | FY2024 | YoY Change |
|---|---|---|
| Revenue | ¥1,036.2B (~$6.84B) | +12% |
| Operating Profit | ¥157.7B | Record high |
| Adjusted Operating Profit | ¥203.4B | Record high |
| Adjusted Operating Margin | ~19.6% | Approaching 20% target |
FY2025 Nine-Month Progress (April – December 2025)
| Metric | 9M FY2025 | YoY Change |
|---|---|---|
| Revenue | ¥831.6B | +7.7% |
| Adjusted Operating Profit | ¥173.5B | +8.9% |
Terumo crossed the symbolic ¥1 trillion revenue threshold in FY2024 — a milestone that validates its transformation from a domestic medical supplier to a global medtech powerhouse. Operating margins continue to expand toward the 20%+ target set in the GS26 growth strategy. In USD terms, annual revenue stands at approximately $6.84 billion, positioning Terumo among the world’s top 20 medical device companies.
Revenue Trend (USD)
| Fiscal Year | Revenue (USD) | Growth |
|---|---|---|
| FY2020 | ~$4.8B | — |
| FY2021 | ~$5.3B | +10% |
| FY2022 | ~$5.5B | +4% |
| FY2023 | ~$6.4B | +16% |
| FY2024 | ~$6.84B | +7.5% |
Regional Strategy & Global Footprint
Terumo generates the majority of its revenue outside Japan, reflecting its successful globalization strategy over the past two decades. The Americas region, led by the United States, is now the single largest revenue contributor.
Regional Revenue Breakdown (FY2024)
| Region | Share of Revenue | Key Drivers |
|---|---|---|
| Americas | ~35% | TIS interventional devices, TBCT plasma collection (Rika), OrganOx |
| Japan | ~20% | Hospital Care, diabetes care, domestic pharmaceutical partnerships |
| Europe | ~25% | Terumo Aortic (Scotland/France), interventional cardiology |
| Asia & Others | ~15% | Emerging market expansion, India, Southeast Asia |
| China | ~5% | Growing interventional cardiology market |
The Americas region achieved double-digit local-currency growth in Q1 FY2026, with all business units contributing. Terumo’s U.S. presence spans major manufacturing facilities, the TIS headquarters, and the recently acquired OrganOx operations. In 2023, Terumo expanded into South Africa with a new subsidiary, reflecting its strategy to capture growth in underserved emerging markets.
GS26: Five-Year Growth Strategy
Announced in December 2021 to coincide with Terumo’s 100th anniversary, the GS26 (Growth Strategy 2026) is a five-year plan with a ten-year vision. The strategy is built around three pillars:
| Pillar | Description |
|---|---|
| Delivery | Next-generation drug delivery systems including PLAJEX pre-filled syringes |
| Digital | Integration of AI, data analytics, and connected devices across product lines |
| Deviceuticals | Convergence of devices and pharmaceuticals — a new category Terumo is pioneering |
GS26 Financial Targets
- Revenue growth — High single-digit annual growth
- Operating margin — 20%+ (adjusted basis)
- ROIC — 10% or higher
- Vision — “From Devices to Solutions” — shifting from selling hardware to providing integrated healthcare solutions
With FY2024 revenue already surpassing ¥1 trillion and adjusted operating margin approaching 20%, Terumo is on track to meet or exceed most GS26 targets ahead of the strategy’s conclusion in March 2027.
M&A Strategy: Building a Global Platform
Terumo has executed a disciplined series of acquisitions to fill product gaps, enter new therapeutic areas, and build scale in key geographies. Each deal has been strategically integrated into Terumo’s existing business segments.
| Year | Target | Value | Strategic Rationale |
|---|---|---|---|
| 2006 | MicroVention | Undisclosed | Entry into neurovascular intervention (cerebral aneurysm coils) |
| 2011 | CaridianBCT (Gambro BCT) | ~$2.6B | Created Terumo BCT; became global #1 in blood component technology |
| 2016 | Sequent Medical | $280M | Intrasaccular flow disruptors for aneurysm treatment (via MicroVention) |
| 2017 | Bolton Medical | $174M | Aortic stent grafts; merged with Vascutek to form Terumo Aortic |
| 2025 | OrganOx | $1.5B | Organ transplant perfusion; metra system keeps donor livers viable |
OrganOx: The Transformative Deal
The $1.5 billion acquisition of UK-based OrganOx, completed in October 2025, represents Terumo’s largest and most transformative deal. OrganOx’s metra normothermic machine perfusion (NMP) system allows surgeons to keep donor livers functioning at body temperature outside the body, enabling better assessment of organ viability and expanding the pool of transplantable organs. In Q3 FY2025, OrganOx revenue grew 50% year-over-year with an adjusted operating margin of 21% — validating the acquisition thesis within months.
MicroVention → Terumo Neuro Rebrand
In September 2024, MicroVention officially rebranded to Terumo Neuro, reflecting its expanded focus beyond hemorrhagic stroke treatment to encompass the full neurovascular patient care continuum. The rebrand signals Terumo’s intent to build a comprehensive neurovascular platform rivaling Medtronic and Stryker.
Product Portfolio Deep Dive
Transradial Intervention (TRI) — Defining the Standard of Care
Terumo is widely recognized as the global pioneer and leader in transradial intervention (TRI) — performing catheterization procedures through the radial (wrist) artery rather than the femoral (groin) artery. Benefits include:
- Lower complication rates — Significantly reduced bleeding and vascular access site complications
- Faster patient recovery — Patients can walk immediately after the procedure
- Cost savings — Shorter hospital stays and reduced need for vascular closure devices
For over 30 years, Terumo Interventional Systems has trained thousands of interventional cardiologists worldwide in the radial approach. The company offers a complete ecosystem of guide wires, guide catheters, sheaths, and hemostasis devices optimized for radial access. More recently, Terumo has pioneered distal radial access (via the anatomical snuffbox), further reducing complications.
Blood & Cell Technologies — From Transfusion to Transplant
Terumo BCT serves blood centers, hospitals, and therapeutic apheresis providers worldwide. The Rika automated plasma collection system has been a major growth driver in the U.S. market, where plasma-derived therapies are experiencing surging demand. With OrganOx now integrated, Terumo is building a unique “blood-to-organs” continuum — managing biological products from collection through preservation and transplantation.
Competitive Landscape
Terumo competes with the world’s largest medical device companies across multiple product categories. While smaller than Medtronic or Johnson & Johnson in absolute terms, Terumo holds dominant positions in specific niches.
| Company | FY2024 Revenue | Key Overlap Areas | Terumo’s Position |
|---|---|---|---|
| Medtronic | $32.4B | Cardiovascular, neurovascular | Smaller but #1 in transradial; niche leader in neurovascular coils |
| Boston Scientific | $16.7B | Interventional cardiology, stents | Competitive in coronary intervention; Terumo leads in radial access |
| Abbott | $19.0B (devices) | Vascular, structural heart | Complementary more than competitive |
| Becton Dickinson | $20.2B | Syringes, infusion, blood collection | Direct competitor in medical disposables |
| Baxter | $14.8B | IV solutions, renal care | Overlaps in infusion and peritoneal dialysis |
Competitive Advantages
- Niche dominance — #1 global position in transradial catheterization and blood component technology
- Vertical integration — Manufactures from raw materials to finished devices, ensuring quality control
- Clinical education leadership — 30+ years of physician training programs in radial access create deep loyalty
- Japanese quality reputation — “Made in Japan” precision manufacturing across global facilities
- Disciplined M&A — Acquisitions are integrated into existing platforms rather than operated as standalone businesses
Business Opportunities for International Partners
Terumo’s scale, technological depth, and global infrastructure present multiple collaboration avenues for international partners:
For Medical Device Distributors
- Emerging market distribution — Terumo is actively expanding in Africa, Southeast Asia, and Latin America. Local distributors with regulatory expertise and hospital relationships are valued partners
- Full-line cardiology portfolio — From guide wires to stent grafts, Terumo offers a complete interventional suite that distributors can cross-sell
For Healthcare Investors
- Stable growth profile — High single-digit revenue growth with expanding margins and disciplined capital allocation
- OrganOx upside — The organ transplant preservation market is early-stage with significant growth potential as the metra system gains broader adoption
- Currency tailwinds — A weak yen environment amplifies overseas earnings when reported in JPY
For Pharmaceutical Companies
- PLAJEX pre-filled syringe platform — Terumo’s pre-filled syringe technology (Medical Care Solutions segment) offers pharmaceutical partners a turnkey drug delivery solution with strong overseas growth
- Deviceuticals collaboration — Terumo’s GS26 strategy explicitly targets the convergence of devices and drugs, creating opportunities for joint development
For Technology Companies
- Digital health integration — Terumo’s Digital pillar in GS26 seeks AI, data analytics, and connected device partnerships
- Cell therapy automation — TBCT’s cell processing platforms need software and automation partners as the regenerative medicine market scales
Outlook & Key Risks
Growth Catalysts
- OrganOx commercialization — Expanding metra adoption beyond liver to potentially kidney and heart perfusion
- Neurovascular expansion — Terumo Neuro’s broader product portfolio for ischemic and hemorrhagic stroke
- Emerging market penetration — Africa, India, and Southeast Asia represent massive underserved populations
- Radial access proliferation — Transradial adoption is still below 50% in many countries, providing a long runway for TIS growth
- Cell & gene therapy — TBCT’s processing platforms are positioned for the next wave of advanced therapies
Key Risks
- Currency volatility — Approximately 80% of revenue is generated outside Japan, exposing earnings to FX fluctuations
- Regulatory complexity — Operating across 160+ countries requires navigating diverse and evolving regulatory frameworks
- Competitive pressure — Medtronic, Boston Scientific, and Abbott are investing heavily in overlapping product categories
- China market uncertainty — Volume-based procurement policies in China continue to pressure pricing
- Integration risk — The $1.5B OrganOx acquisition must be successfully integrated while maintaining growth
Conclusion
Terumo Corporation exemplifies the power of Japanese precision engineering applied to global healthcare challenges. From a thermometer company founded out of wartime necessity to a ¥1 trillion medtech leader operating in 160+ countries, Terumo’s century-long journey is a masterclass in disciplined growth, strategic M&A, and clinical innovation. The company’s dominance in transradial catheterization, its expanding presence in organ transplant technology through OrganOx, and its GS26 vision of converging devices, drugs, and digital solutions position it for continued relevance in 21st-century healthcare. For international partners seeking a Japanese medtech collaborator with global scale, deep clinical relationships, and a proven integration track record, Terumo represents one of the most compelling opportunities in the industry.
About This Report
This deep-dive analysis was produced by the Japonity research team as part of our Japan Company Intelligence series. Japonity helps global businesses discover, evaluate, and connect with leading Japanese companies across technology, healthcare, food, and manufacturing sectors.
Need a Custom Research Report?
Japonity offers bespoke research and analysis services for companies exploring Japanese market entry, partnership opportunities, or competitive intelligence. Contact us to discuss your requirements.
Interested in Japanese business opportunities?
Whether you're looking for technology partners, engineering talent, or market insights — we can help connect you with the right Japanese organizations.
Get in Touch →
